全文获取类型
收费全文 | 7211篇 |
免费 | 52篇 |
国内免费 | 79篇 |
专业分类
系统科学 | 142篇 |
丛书文集 | 210篇 |
教育与普及 | 387篇 |
理论与方法论 | 21篇 |
现状及发展 | 655篇 |
研究方法 | 902篇 |
综合类 | 5019篇 |
自然研究 | 6篇 |
出版年
2021年 | 10篇 |
2017年 | 13篇 |
2016年 | 12篇 |
2014年 | 25篇 |
2013年 | 24篇 |
2012年 | 471篇 |
2011年 | 557篇 |
2010年 | 167篇 |
2009年 | 106篇 |
2008年 | 611篇 |
2007年 | 573篇 |
2006年 | 595篇 |
2005年 | 657篇 |
2004年 | 458篇 |
2003年 | 419篇 |
2002年 | 375篇 |
2001年 | 260篇 |
2000年 | 396篇 |
1999年 | 141篇 |
1998年 | 50篇 |
1997年 | 27篇 |
1996年 | 31篇 |
1995年 | 17篇 |
1994年 | 23篇 |
1993年 | 19篇 |
1992年 | 26篇 |
1991年 | 29篇 |
1990年 | 31篇 |
1989年 | 48篇 |
1988年 | 33篇 |
1987年 | 33篇 |
1986年 | 35篇 |
1985年 | 33篇 |
1984年 | 42篇 |
1983年 | 26篇 |
1982年 | 39篇 |
1981年 | 33篇 |
1980年 | 20篇 |
1979年 | 23篇 |
1971年 | 21篇 |
1970年 | 41篇 |
1966年 | 18篇 |
1960年 | 11篇 |
1959年 | 79篇 |
1958年 | 168篇 |
1957年 | 96篇 |
1956年 | 103篇 |
1955年 | 97篇 |
1954年 | 98篇 |
1948年 | 40篇 |
排序方式: 共有7342条查询结果,搜索用时 15 毫秒
91.
92.
93.
94.
95.
Mullighan CG Goorha S Radtke I Miller CB Coustan-Smith E Dalton JD Girtman K Mathew S Ma J Pounds SB Su X Pui CH Relling MV Evans WE Shurtleff SA Downing JR 《Nature》2007,446(7137):758-764
Chromosomal aberrations are a hallmark of acute lymphoblastic leukaemia (ALL) but alone fail to induce leukaemia. To identify cooperating oncogenic lesions, we performed a genome-wide analysis of leukaemic cells from 242 paediatric ALL patients using high-resolution, single-nucleotide polymorphism arrays and genomic DNA sequencing. Our analyses revealed deletion, amplification, point mutation and structural rearrangement in genes encoding principal regulators of B lymphocyte development and differentiation in 40% of B-progenitor ALL cases. The PAX5 gene was the most frequent target of somatic mutation, being altered in 31.7% of cases. The identified PAX5 mutations resulted in reduced levels of PAX5 protein or the generation of hypomorphic alleles. Deletions were also detected in TCF3 (also known as E2A), EBF1, LEF1, IKZF1 (IKAROS) and IKZF3 (AIOLOS). These findings suggest that direct disruption of pathways controlling B-cell development and differentiation contributes to B-progenitor ALL pathogenesis. Moreover, these data demonstrate the power of high-resolution, genome-wide approaches to identify new molecular lesions in cancer. 相似文献
96.
97.
98.
99.
100.
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 总被引:1,自引:0,他引:1
Oncogenic tyrosine kinases have proved to be promising targets for the development of highly effective anticancer drugs. However, tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (HER) family show only limited activity against HER2-driven breast cancers, despite effective inhibition of epidermal growth factor receptor (EGFR) and HER2 in vivo. The reasons for this are unclear. Signalling in trans is a key feature of this multimember family and the critically important phosphatidylinositol-3-OH kinase (PI(3)K)/Akt pathway is driven predominantly through transphosphorylation of the kinase-inactive HER3 (refs 9, 10). Here we show that HER3 and consequently PI(3)K/Akt signalling evade inhibition by current HER-family TKIs in vitro and in tumours in vivo. This is due to a compensatory shift in the HER3 phosphorylation-dephosphorylation equilibrium, driven by increased membrane HER3 expression driving the phosphorylation reaction and by reduced HER3 phosphatase activity impeding the dephosphorylation reaction. These compensatory changes are driven by Akt-mediated negative-feedback signalling. Although HER3 is not a direct target of TKIs, HER3 substrate resistance undermines their efficacy and has thus far gone undetected. The experimental abrogation of HER3 resistance by small interfering RNA knockdown restores potent pro-apoptotic activity to otherwise cytostatic HER TKIs, re-affirming the oncogene-addicted nature of HER2-driven tumours and the therapeutic promise of this oncoprotein target. However, because HER3 signalling is buffered against an incomplete inhibition of HER2 kinase, much more potent TKIs or combination strategies are required to silence oncogenic HER2 signalling effectively. The biologic marker with which to assess the efficacy of HER TKIs should be the transphosphorylation of HER3 rather than autophosphorylation. 相似文献